Sun Pharma Launches New Treatment for Erosive Esophagitis in India

Sun Pharmaceutical Industries, one of India’s leading drug manufacturers, announced the launch of a new medication for the treatment of Erosive Esophagitis across all grades. The company introduced Fexuprazan tablets (40 mg) under the brand name Fexuclue in the Indian market.

In a statement released on Monday, the Mumbai-based pharmaceutical giant said Fexuclue is a novel potassium-competitive acid blocker (PCAB) — a new class of medication designed to manage acid-related gastrointestinal conditions more effectively.

The drug has been approved for use in adults suffering from Erosive Esophagitis, a condition where inflammation and damage occur in the lining of the esophagus due to acid reflux. Fexuclue offers a promising alternative to existing treatments, providing relief from symptoms and helping to heal esophageal damage.

The launch reinforces Sun Pharma’s commitment to introducing innovative therapies that address unmet medical needs and improve patient outcomes in India.